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Abstract 
Long non coding RNAs (lncRNAs) are a functionally diverse family of non-coding 
RNAs, which have been implicated in modulating gene expression through 
transcription, translation and DNA epigenetic modifications.  As a relatively nascent 
field, the number of known functional lncRNAs is currently small. However, 
increasing numbers of lncRNAs are now being identified as candidate regulators of 
inflammatory pathways that are relevant to osteoarthritis and rheumatoid arthritis 
joint pathology.  Furthermore, several lncRNAs have been identified which are 
differentially expressed in osteoarthritis or rheumatoid arthritis joint tissue.   
  
In this review, we highlight those lncRNAs for which functional effects have been 
demonstrated within the major pathways associated with inflammation, including 
NFkB signalling, p38 MAPK pathway, arachidonic acid pathway and TLR signalling. 
We also highlight those lncRNAs which have been shown to be differentially 
expressed in inflammatory joint tissue, and are therefore strong candidates for future 
investigative work.  
  
Determining the expression and functional role of lncRNAs in mediating inflammation 
within the joint will not only advance our understanding of the epigenetics which 
underlie the pathology of inflammatory joint disease, but may also ultimately aid 
in the identification of novel targets for therapeutic intervention.   
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1.  Introduction 
It was initially envisaged that upon the completion of the human genome project our 
understanding of human disease would lead to an abundant development of new 
targeted therapies by which to modify disease progression or prevent disease onset.  
Furthermore, advances in Next Generation Sequencing (NGS) have allowed for 
large-scale DNA and RNA transcriptome analysis of multiple tissue and cell types 
encompassing a myriad of disease states, leading to an increased understanding of 
the composition and regulation of the human genome.  However, as a result of such 
studies it has become increasingly apparent that many chronic diseases are likely to 
be the result of the interaction between intrinsic genes and the external environment, 
which can result in modification to the DNA sequence and impact on gene 
expression.   
 
This understanding has led to the emergence of the research field known as 
epigenetics, which includes the analysis of DNA modifications (including methylation 
and histone acetylation), as well as the transcription of non-coding RNAs.  Indeed, 
the protein coding elements of the human genome are now known to be restricted to 
just 2% of the total genetic material present. Initially the remaining DNA was thought 
to be mostly “junk”, but much of this so called “genomic dark matter” is now known to 
transcribe multiple families of non-coding RNAs(1), many of which have been shown 
to modulate gene expression (Figure 1).   
 
One such family of non-coding RNAs is the microRNA family(2), which bind to and 
prevent the translation of target mRNAs (Figure 2A).  Importantly, there is now 
overwhelming evidence that microRNAs are regulators of the inflammatory 
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response(3), and several have been associated with multiple inflammatory diseases 
including osteoarthritis (OA)(3), rheumatoid arthritis (RA)(4). 
 
However, recent NGS studies have now identified a new family of non-coding RNA, 
known as long non-coding RNAs (lncRNAs)(5), which are defined as transcripts 
>200 nt in length (Figure 1A).  Over 14,000 have thus far been identified in 
humans(6), and they are currently sub-classified, based on their position relative to 
protein coding genes (Figure 1B), into antisense lncRNAs, pseudogene lncRNAs, 
enhancer RNAs, intronic lncRNAs and long intergenic ncRNA (lincRNA).  These 
multiple variants may in part explain the functional diversity that has thus far been 
assigned to lncRNAs(7), including inhibition of transcriptional machinery, functioning 
as miRNA sponges, affecting mRNA stability and epigenetic DNA modifications 
(Figure 2B, C, D).  Many of these functions have been attributed to the theory that 
lncRNAs form flexible scaffolds, which can bind proteins and RNAs.   
 
Importantly, increasing evidence suggests that lncRNAs are important regulators of 
pathological and physiological processes, and evidence is now emerging to suggest 
that lncRNAs are central regulators of the inflammatory response.  Therefore, in this 
review, we examine the evidence for the role of lncRNAs as regulators of 
inflammatory joint disease by highlighting studies which have reported differential 
expression of lncRNAs in diseased inflammatory joint tissue of patients with RA and 
OA, as well as studies which have implicated lncRNAs as regulators of known 
inflammatory pathways relevant to joint pathology. LncRNAs are poorly conserved 
across species, which has limited studies to determine their function. This poor 
conservation places great importance on the requirement to validate the function of 
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lncRNAs in disease-relevant human cells and tissue(8).  For this reason, this review 
will focus on lncRNA data generated from human tissue/cells.   
 
2.  LncRNAs regulate inflammatory pathways 
Inflammation is a central hallmark of RA joint disease, and evidence for inflammatory 
pathway dysregulation and cell dysfunction has been found in almost all innate and 
adaptive immune cells including. In addition, despite historically being seen as a 
“wear and tear” disease of the cartilage, there is now substantial evidence for 
inflammation also being a key contributor to OA joint pathology(9).  OA synovial 
inflammation (synovitis) has been shown histologically, as well as by ultrasound and 
MRI imaging(10, 11), and there is evidence for increased cellular infiltration of 
activated B cells and T lymphocytes, and elevated levels of pro-inflammatory 
cytokines in the synovial fluid(12).  Furthermore, ex-vivo stimulation of cartilage 
tissue with pro-inflammatory cytokines mimics several pathological features of the 
OA joint(13), and inhibitors of inflammatory pathways have modified OA disease in 
preclinical models(14). 
 
Below we examine the current evidence for the role of lncRNAs in regulating 
canonical inflammatory pathways that are relevant to inflammatory joint pathology. 
Of the major signaling pathways that are known to govern joint inflammation four 
pathways were currently highlighted as having lncRNAs associated with their 
regulation, namely NFκB signalling, p38 MAPK pathway, the arachidonic acid 
pathway and TLR signalling.  
 
2.1 NFκB Pathway 
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NFκB is considered a master regulator of inflammation, and its activity has been 
shown to regulate the production of several pro-inflammatory cytokines implicated in 
OA and RA joint pathology, including IL-1β, IL-6, IL-17 and TNF-α(12, 15). 
Therefore, inhibition of NFκB signalling has long been considered an attractive 
pathway to develop a therapeutic for chronic inflammatory disorders(15).  However, 
therapeutic targeting of NFκB presents a challenge since NFκB may also have an 
anti-inflammatory role and be important for the resolution of inflammation(16). 
Therefore, identifying new approaches to appropriately target the pro-inflammatory 
activity of NFkB within the joint(17), so that systemic effects are avoided and patients 
are not immunocompromised, is important. 
 
Thus far, several lncRNAs have been identified and implicated in targeting different 
components of the NFκB signalling pathway (Figure 3A). Of most immediate interest 
for inflammatory joint disease is lincRNA-p21, whose ability to inhibit NFκB signalling 
by sequestering RelA (the p65 subunit of NFκB) in T cells has been demonstrated 
following methotrexate treatment in RA patients. LincRNA-p21 expression was 
shown to be upregulated by methotrexate via a DNA-dependent protein kinase 
catalytic subunit (DNA PKcs)-dependent mechanism (18). 
 
Another lncRNA which has been implicated as regulating NFκB activity is the 
pseudogene Lethe, which has been shown to be expressed in fibroblasts.  
Functional studies have demonstrated that Lethe interacts with and blocks the DNA 
binding of RelA (p65).  It is believed that Lethe acts as part of a negative feedback 
loop which acts to regulate the inflammatory response, whereby following NFκB 
activation by pro-inflammatory cytokines, upregulation of Lethe inhibits NFκB 
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signalling. Of interest, the tissue expression of Lethe has been shown to be 
downregulated in aged mice (19). If the same is true in human ageing, the reduction 
in the expression of this potential brake on NFκB activity could be a contributing 
factor to age-associated inflammatory joint disorders such as RA and OA.  Finally, 
studies conducted in human inflammatory breast epithelial cells have shown that the 
lncRNA NKILA (NFκB-interacting lncRNA) binds to and blocks phosphorylation sites 
on IκB, thereby inhibiting IKK-induced IκB phosphorylation and NFκB activation (20). 
Thus far, there are no studies which have reported the functional role of lincRNA-
p21, Lethe or NKILA in RA or OA joint tissues or cells.   
 
2.2 Arachidonic Acid Pathway 
Arachidonic acid metabolites (prostaglandins and leukotrienes), are known 
mediators of the inflammatory response(21), and several have been found to be 
differentially expressed in the joints of patients with either OA or RA(22). Therefore, 
targeted inhibition of the arachidonic acid pathway has long been considered an 
important area of research for developing a therapeutic that combats joint 
inflammation and pain.  Indeed, inhibition of the prostaglandin synthase enzymes 
(COX enzymes) is the basis for the mode of action of non-steroidal anti-inflammatory 
drugs (NSAIDs) such as Ibuprofen(23) and selective PTGS2 (COX2) inhibitors such 
as Valdecoxib(24), which have shown efficacy in reducing joint inflammation in 
several clinical trials. 
 
Of importance therefore was the recent finding that the expression of PTGS2 
(COX2) was positively regulated by a p50-associated COX-2 extragenic lncRNA 
(Figure 3B), referred to as PACER (25). PACER was shown to bind to and remove 
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the repressive action of the p50 homodimer (of NFκB), at the COX2 promoter, 
leading to activation of COX-2 gene expression.  Furthermore, we recently found that 
the expression of PACER was associated with the IL-1β-mediated inflammatory 
response in primary human OA chondrocytes, and differentially expressed in human 
OA cartilage compared to non-OA cartilage (26).  
 
Unfortunately, long-term administration of non-selective NSAIDs are associated with 
gastrointestinal toxicity(27), whilst selective COX2 inhibitors increase the risk of 
cardiovascular adverse events(28), attributed to a resulting imbalance between 
Thromboxane and prostacyclin levels. Therefore, identifying new regulators of 
prostaglandin production, such as PACER, is important, since it may lead to new 
targeted approaches that are capable of selectively inhibiting the production of 
inflammation-associated arachidonic acid metabolites, without any resulting toxicity. 
 
2.3 p38 MAPK Signalling 
 Several studies have provided evidence that the p38 MAPK pathway is central to 
mediating both the production of pro-inflammatory cytokines and their signal 
transduction in the joint(13).  Furthermore p38 small molecule inhibitors have shown 
efficacy both in reducing cartilage degeneration in OA preclinical models(29, 30), 
and reducing inflammatory pain in RA models(14, 31), albeit clinical trials of p38 
inhibitors in patients with RA have thus far failed in the clinic. 
 
With regards to lncRNA regulation of the p38 pathway, recent studies suggest the 
involvement of the metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) (32) (Figure 3C). MALAT1 is one of the most abundantly expressed 
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lncRNAs, with high levels of conservation across multiple tissue types. It has 
previously been well characterised in cancer where it is a transcription regulator 
implicated in cell cycle control and metastasis. However, Liu and colleagues (2014) 
have now highlighted MALAT1 cross-talk with p38 MAPK as being pathogenic in 
diabetes mellitus. MALAT1 is believed to activate p38 MAPK, since siRNA mediated 
knockdown of MALAT1 reduced p38 phosphorylation (32).  Furthermore, MALAT1 
expression has been found to be implicated in inflammation, again in diabetes 
mellitus under hyperglycaemic conditions, where it was shown to contribute to 
increased IL-6 expression and reactive oxygen species (ROS) generation(33). 
 
2.4 TLR Signalling 
Innate immune cells such as macrophages and neutrophils are present in the 
inflamed joints of RA and OA patients, and it is known that Toll-like receptor (TLR) 
signalling plays a key role in the recruitment and activation of these cells. Therefore, 
understanding the regulation of cytokine and chemokine signalling by these cells will 
provide greater clues as to the onset and maintenance of chronic inflammation within 
the joint. 
 
TNFα and hnRNPL related immunoregulatory LincRNA (THRIL) was recently 
identified in macrophages as a lncRNA which could form a complex with 
heterogeneous ribonucleoprotein L (hnRNPL) within the nucleoplasm (Figure 3D).  
hnRNPs are known to be important for the processing, function and stabilisation of 
mRNAs. Critically, it was demonstrated that the THRIL/hnRNPL complex binds to the 
promotor of TNFα and induces its expression following TLR2 activation(34). 
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Carpenter and colleagues(35) identified a lncRNA (lincRNA-COX2) that sits in close 
proximity to the PTGS2 gene but, unlike the aforementioned PACER, this lncRNA 
had no functional interaction with PTGS2.  Instead, lncRNA-COX2 was shown to be 
upregulated following activation of the TLR2 pathway (Figure 3D). Furthermore, 
following knockdown of lincRNA-COX2 and under the challenge of a synthetic TLR2 
antagonist, expression of IL-6 became undetectable, while CCL5 expression 
increased. Similarly to THRIL, lincRNA-COX2 forms complexes with hnRNPs, 
specifically hnRNP-A/B and hnRNP-A2/B1, and the formation of such complexes has 
been shown to modulate target gene expression. 
 
Activation of TLR3 has been shown to induce a lncRNA referred to as NEAT1 
(nuclear enriched abundant transcript 1).  NEAT1 was found to bind to a repressor of 
IL-8 transcription known as SFPQ (splicing factor proline/glutamine-rich) and 
relocate it to paraspeckle bodies (Figure 3D), resulting in IL-8 transcriptional 
activation(36). Ilott and colleagues(37) demonstrated that TLR4 activation in 
monocytes up-regulated expression of a lncRNA known as IL1β-RBT46. IL1β-
RBT46 shares a promotor with the IL-1β coding gene and following pathway 
activation, both expression of the lincRNA and the IL-1β gene are induced (Figure 
3D).  LNA-mediated knockdown of IL1β-RBT46 led to a decrease in IL-1β mRNA 
expression, suggesting that the lincRNA promotes expression of the gene. A further 
consequence of IL1β-RBT46 knockdown was a reduction in expression of IL-8, a 
well-defined neutrophil chemoattractant. 
 
Taken together, the lncRNAs described above represent a pool of lncRNAs, which 
have not as yet been associated with inflammatory joint disease. However, given 
Page 10 of 51
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
11 
 
their prevalence in the regulation of central pathways of inflammation, determining 
their expression in joint tissues, and the relationship to OA and/or RA joint pathology 
would appear to be important studies.   
 
The significance of genetic variations in the sequences of lncRNAs is currently not 
well understood and has been little studied to date.  There is evidence that large 
alterations such as chromosomal rearrangements can affect lncRNA expression(38).  
However, as illustrated by the functional studies highlighted in this review, lncRNA 
function may largely be determined by its secondary structure, through binding to 
proteins and RNA.  Therefore, smaller mutations and genetic variations such as 
SNPs may have little effect on lncRNA function.  It is conceivable that SNPs could 
alter lncRNA function by altering lncRNA secondary structure, or causing alternative 
splicing of the lncRNA.  Indeed, there is evidence of SNPs in the chromosomal 
region that harbour the lncRNA ANRIL being associated with a susceptibility to 
cardiovascular disorders(39).  However, it is not currently known whether these 
SNPs impact on the functional role of ANRIL lncRNA, or simply affect its expression.   
Predominantly therefore, studies have thus far linked lncRNA to disease by 
expression analysis. 
 
3.  LncRNA expression in inflammatory OA and RA joint tissues 
Transcriptional analyses by both NGS and microarray have identified several 
lncRNAs that are differentially expressed in inflammatory diseased joint tissue.  Thus 
far, studies on OA patient samples have focussed on the cartilage tissue, whilst in 
RA disease other peri-joint tissues such as synovium and sub-chondral bone have 
been interrogated.   
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One lncRNA that has been found to be differentially expressed in both OA and RA 
joint tissue is HOTAIR.  Located on chromosome 12, HOTAIR was the first lncRNA 
to be characterised, and has been shown to interact with polycomb repressive 
complex 2 (PRC2) which regulates the chromatin state, and the histone 
demethylase, LSD1. As such, it regulates epigenetic changes within its target 
transcripts(40).  
 
In OA cartilage, HOTAIR was found to be upregulated compared to non-OA cartilage 
(41), although as yet its function in cartilage tissue or in isolated chondrocyte cells 
has yet to be reported.  Song et al (42) have also identified differential expression of 
HOTAIR in RA peri-joint tissues, namely synovial fibroblasts, osteoclasts and bone 
mononuclear cells. Of note, Song et al (42) found that the function of HOTAIR 
differed depending on the RA cell studied. For example, in RA synovial fibroblasts 
and osteoclasts, HOTAIR expression was lower than in controls and its over-
expression decreased the expression of MMP2 and MMP13.  In contrast, HOTAIR 
was upregulated in RA bone mononuclear cells where it functioned to facilitate 
macrophage activation and migration towards the joint. 
 
Another lncRNA for which differential expression has been reported in inflamed joint 
tissue is H19.  H19 lncRNA has been found to be highly expressed in RA synovial 
tissues RA(43) and in OA cartilage(44).  Previous studies have demonstrated that 
H19 is a developmental reservoir of the two miR-675 family members – miR-675-p3 
and miR-675-p5, which have been shown to regulate Type II Collagen expression 
and mediate cellular development in multiple tissues (45-47).  Of interest, numerous 
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studies have demonstrated that H19 controls the expression of several genes which 
are part of the Imprinted Gene Network (IGN) – a series of parentally inherited genes 
whose expression is epigenetically determined within the sperm or oocyte. Such 
“imprinting disorders” have been linked to a number of human pathologies. Currently, 
inflammatory disease isn’t known to be affected by imprinting disorders, but given 
the inheritability of RA and other inflammatory diseases, studies which investigate 
the role of H19 in determining epigenetic susceptibility to disease could be of 
interest. 
  
As previously mentioned, lncRNA analysis in OA has primarily focused on the 
cartilage tissue, and the lncRNAs GAS5(48) and MEG3(49) have been reported to 
be downregulated in OA diseased cartilage. Fu and colleagues(50) performed 
microarray analysis  and identified 4714 lncRNAs which were differentially expressed 
in OA cartilage compared to non-OA cartilage.  Although this study did not perform 
any modulation of lncRNA expression to determine lncRNA function, expression 
correlation patterns were utilised to predict candidate lncRNA regulated genes.   This 
analyses highlighted lncRNAuc.343, which was upregulated in OA cartilage, as 
regulating in cis the expression of HOXC8(50), and that many of the differentially 
expressed lncRNAs worked in concert with the transcription factor, SP1, to modulate 
expression of trans target genes. 
 
In a separate study, microarray analysis was used to identify a lncRNA with a 
specific role in the degradation of the cartilage matrix, named lncRNA-CIR.  
LncRNA-CIR was found to be upregulated in OA cartilage, compared to non-OA 
cartilage, and siRNA-mediated knockdown of its expression resulted in the increased 
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expression of collagen and aggrecan accompanied by reduced expression of 
MMP13 and ADAMTS5 (51). 
  
Furthermore, we recently identified lncRNAs associated with the IL-1β-mediated 
inflammatory response in primary human OA chondrocytes, which were also 
differentially expressed in OA diseased cartilage.  Of particularly note were 
HIVEP2AS and IL-7AS, two intergenic lncRNAs proximal to the Hivep2 and IL-7 
protein coding genes respectively(26).  Both HIVEP2AS and IL-7AS were found to 
be upregulated in both Knee OA and hip OA cartilage compared to non-OA control 
cartilage(26).  Furthermore, LNA-mediated knockdown of HIVEP2AS and IL-7AS 
expression in human chondrocytes resulted in an increase in the production of pro-
inflammatory cytokines, including IL-6(26), suggesting that these lncRNAs may 
function to control aberrant joint inflammation.   
 
4.  Perspectives 
LncRNA research in inflammatory joint disease is very much a nascent field.  
However, several lncRNAs have now been identified as being either differentially 
expressed in diseased joint tissue, or as candidate central regulators of inflammatory 
pathways relevant to joint pathology.  Therefore, future studies to determine the 
functional role and mode of action of these disease-associated lncRNAs will be 
insightful, as will joint tissue expression profiling of lncRNAs for which functional 
roles within key inflammatory pathways have been determined.  To this end, it will be 
important to conduct further transcriptomic analysis of joint tissues (including 
subchondral bone, cartilage, and synovium), where diseased joint tissues are 
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compared with age-matched non-inflammatory control joint tissue, and to conduct 
functional mode-of-action studies in disease relevant cells.   
 
It should be noted that currently the expression analysis of lncRNAs in the joint 
tissues from patients with other inflammatory joint diseases including gout, psoriatic 
arthritis and juvenile idiopathic arthritis has not yet been reported. Clearly, such 
studies could also prove to be informative in building a broader pool of inflammatory 
joint disease-associated lncRNAs.  Indeed, since inflammatory joint diseases share 
several common pathways, such studies are likely to identify lncRNAs that are 
dysregulated across multiple inflammatory joint disorders.  Such findings will add to 
the recent paradigm shift in our understanding of the dysregulation of chronic 
disease, whereby the disease is no longer classified solely by its gross pathology but 
by the involvement of a particular dysregulated pathway.    
 
It is currently too early to determine whether disease modifying therapeutics could be 
developed that are designed to directly target and modulate lncRNA function.  
Recent progress has been achieved using siRNA RNAi-based therapeutics, whereby 
targeted knockdown of TNF-α (52) or NFĸB (53) has modified disease progression in 
animal models of RA and OA.  Therefore, it is conceivable that lncRNAs could 
provide a new class of targets for RNAi based therapeutics.  Regardless, ultimately 
determining the mode of action of lncRNAs that regulate inflammatory pathways,  
and determining their relationship to joint pathology will provide a better 
understanding of how inflammation is epigenetically regulated within the joint.  This 
improved understanding will likely be important in aiding the identification of new 
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targets for therapeutic intervention, as well as in identifying at risk patient 
populations.    
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Table 1: LncRNA involvement in inflammatory pathways 
Pathway LncRNA Tissue/Cell Chromosome 
Locus 
Function Reference 
NFκB Signalling LincRNA-
p21 
T cells 6p21.2 Inhibition of NFκB following methotrexate treatment Spurlock et al 
2014(18) 
 NKILA Epithelial cells 20q13.31 Inhibition of IκB phosphorylation Liu et al 
2015(20) 
 Lethe Fibroblasts Not reported Inhibition of RelA DNA binding Rapicavoli et al 
2013(19) 
p38 MALAT1 Endothelial 
cells 
11q13.1 Reduced p38 phosphorylation and inaction of p38 MAPK signalling Liu et al 
2014(32) 
Puthanveetil et al 
2015(33) 
Arachidonic Acid  PACER Epithelial cells 1q31.1 Inhibition of COX-2 Krawczyk et al 
2014(25) 
TLR THRIL Macrophages 12q24.31 Complex formation with hnRNPL to induce TNFα expression Li et al 2014(34) 
 IL1β-RBT46 Monocytes 2q14 Inhibition of IL-1β and IL-8 secretion Ilott  et al  
2014(37) 
 LincRNA-
COX2 
Bone marrow 
dendritic cells 
1q31.1 Up-regulation of IL-6 and down-regulation of CCL5 Carpenter et al 
2013(35) 
 NEAT1 HeLa 11q13.1 Activated by p38 leading to expression of IL-8 Imamura et al 
2014(36) 
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Table 2: Evidence for the differential expression of lncRNAs in OA and RA joint tissues 
Disease LncRNA Tissue/Cell Chromosome 
Locus 
Disease Expression Function Reference 
OA Hivep2-AS (CILinc01) Chondrocytes 6q23-q24 Upregulated Suppresses IL-6, IL-8, TNFα, G-CSF, 
MIP-1β 
Pearson  et al 2016(26) 
 IL-7AS (CILinc02) Chondrocytes 8q12-q13 Upregulated Suppresses IL-6 Pearson et al 2016(26) 
 H19 Chondrocytes 11p15.5 Upregulated Anabolic functions Steck et al 2012(44) 
 LncRNA-CIR Chondrocytes 6q22.32 Upregulated Promotes expression of MMP-13 
and ADAMTS5 while inhibiting 
collagen and aggrecan production 
Liu et al 2014(51) 
 MEG3 Cartilage 14q32.2 Downregulated Inversely correlated with VEGF Su et al 2015(49) 
 HOTAIR Cartilage 12q13.13 Downregulated Unknown Xing et al 2014(41) 
 GAS5 Cartilage 1q25.1 Downregulated Increase expression of MMPs and 
ADAMTS4. Induced apoptosis 
Song et al 2014(48); 
Xing et al 2014(41) 
 lncRNAuc.343 Cartilage Not reported Upregulated Regulation of HOXC8 Fu et al 2015(50) 
RA H19 Synovium 11p15.5 Upregulated Increases expression of NFκB, IL-6, 
TNFα 
Stuhlmüller et al 
2003(43) 
 HOTAIR Synovial fibroblasts, 
osteoclasts 
12q13.13 Downregulated Increased MMP2 and MMP13 
expression 
Song et al 2015(42) 
 HOTAIR Bone mononuclear 
cells 
12q13.13 Upregulated Migration and activation of 
macrophages 
Song et al 2015(42) 
 LincRNA-p21 T cells 6p21.2 Downregulated 
(Upregulated following 
methotrexate treatment) 
Inhibition of NFκB following 
methotrexate treatment  
Spurlock et al 
2014(18) 
Page 22 of 51
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
23 
 
Figure Legends 
 
Figure 1.  Classification of non-coding RNAs and lncRNA sub-types 
(A)  LncRNAs are classified as being >200 nt in length, in contrast to miRNAs which 
are <200 nt long.  (B)  LncRNAs are further classified by their position relative to 
protein-coding genes.  Intronic lncRNAs are transcribed from intronic transcription 
start sites (TSS) and can be in either sense of antisense orientation.  They do not 
intersect any exons.  In contrast, Antisense lncRNAs are transcribed across protein-
coding exons on the opposite strand.  Intergenic lncRNAs (lincRNAs) are transcribed 
from TSS between protein-coding genes.  Pseudogenes can be classified as a type 
of lincRNA and originate when a gene loses its coding ability, for example through a 
mutation.  Enhancer RNAs (eRNAs) can also be considered a type of lincRNA, but 
are transcribed from enhancer regions (identified by the presence of high H3K4me1 
histone marks).  In contrast, other lncRNAs are transcribed from regions associated 
with the presence of high H3K4me3 histone marks, similar to protein-coding genes. 
   
Figure 2.  Functional diversity attributed to lncRNAs. 
(A) Post-transcriptional regulation of gene expression by non-coding miRNAs.  
miRNAs bind to the 3’UTR of target mRNAs in the cytoplasm.  Assembly of a RNA 
induced silencing complex (RISC), composed of Ago2, Dicer and R2D2, leads to 
mRNA degradation.  Conversely, lncRNAs can modulate gene expression through 
both pre- and post-transcriptional regulation mechanisms.  (B) LncRNAs can act as 
scaffolds for the assembly of complexes that epigenetically modify the DNA (e.g  
histone acetylation and methylation), leading to modulation of transcription.  (C) 
LncRNAs can bind to transcription factors and mediate assemble of transcription 
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initiation complexes, leading to modulation of transcription.  (D) LncRNAs can bind to 
miRNAs, acting as either sponges to block their activity, or affect miRNA stability. 
 
Figure 3.  Functional lncRNAs in inflammatory pathways.  (A)  Canonical NFĸB 
signalling.  The lncRNA NKILA blocks the Iĸβα phosphorylation site preventing its 
activation.  The lncRNAs Lethe and LincRNA-p21 both bind to RelA and prevent 
NFĸB binding to NFĸB response elements.  (B)  Arachidonic acid pathway.  The 
lncRNA PACER binds to and removes the repressive action of the p50 homodimer at 
the COX2 promoter, leading to activation of COX-2 gene expression.  (C)  p38 
MAPK signalling.  The lncRNA MALAT1 activates p38 phosphorylation.  ARE 
represents Adenine Rich Elements in mRNA transcripts, which are stabilised via 
downstream MK2 activation.  (D)  TLR signalling.  The lncRNAs THRIL and 
LincRNA-COX2 form complexes with hnRNPLs, which then bind to and activate the 
promoters of pro-inflammatory cytokines TNF-α and CCL5 respectively.  The lncRNA 
NEAT1 binds to SFPQ and relocates it to paraspeckle bodies, relieving its repression 
of the IL-8 promoter.  The IL1β-RBT46 is induced by TLR4 signalling and promotes 
induction of IL-8 and IL-1β via an as yet unknown mechanism. 
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Abstract 
Long non coding RNAs (lncRNAs) are a functionally diverse family of non-coding 
RNAs, which have been implicated in modulating gene expression through 
transcription, translation and DNA epigenetic modifications.  As a relatively nascent 
field, the number of known functional lncRNAs is currently small. However, 
increasing numbers of lncRNAs are now being identified as candidate regulators of 
inflammatory pathways that are relevant to osteoarthritis and rheumatoid arthritis 
joint pathology.  Furthermore, several lncRNAs have been identified which are 
differentially expressed in osteoarthritis or rheumatoid arthritis joint tissue.   
  
In this review, we highlight those lncRNAs for which functional effects have been 
demonstrated within the major pathways associated with inflammation, including 
NFkB signalling, p38 MAPK pathway, arachidonic acid pathway and TLR signalling. 
We also highlight those lncRNAs which have been shown to be differentially 
expressed in inflammatory joint tissue, and are therefore strong candidates for future 
investigative work.  
  
Determining the expression and functional role of lncRNAs in mediating inflammation 
within the joint will not only advance our understanding of the epigenetics which 
underlie the pathology of inflammatory joint disease, but may also ultimately aid 
in the identification of novel targets for therapeutic intervention.   
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1.  Introduction 
It was initially envisaged that upon the completion of the human genome project our 
understanding of human disease would lead to an abundant development of new 
targeted therapies by which to modify disease progression or prevent disease onset.  
Furthermore, advances in Next Generation Sequencing (NGS) have allowed for 
large-scale DNA and RNA transcriptome analysis of multiple tissue and cell types 
encompassing a myriad of disease states, leading to an increased understanding of 
the composition and regulation of the human genome.  However, as a result of such 
studies it has become increasingly apparent that many chronic diseases are likely to 
be the result of the interaction between intrinsic genes and the external environment, 
which can result in modification to the DNA sequence and impact on gene 
expression.   
 
This understanding has led to the emergence of the research field known as 
epigenetics, which includes the analysis of DNA modifications (including methylation 
and histone acetylation), as well as the transcription of non-coding RNAs.  Indeed, 
the protein coding elements of the human genome are now known to be restricted to 
just 2% of the total genetic material present. Initially the remaining DNA was thought 
to be mostly “junk”, but much of this so called “genomic dark matter” is now known to 
transcribe multiple families of non-coding RNAs(1), many of which have been shown 
to modulate gene expression (Figure 1).   
 
One such family of non-coding RNAs is the microRNA family(2), which bind to and 
prevent the translation of target mRNAs (Figure 2A).  Importantly, there is now 
overwhelming evidence that microRNAs are regulators of the inflammatory 
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response(3), and several have been associated with multiple inflammatory diseases 
including osteoarthritis (OA)(3), rheumatoid arthritis (RA)(4). 
 
However, recent NGS studies have now identified a new family of non-coding RNA, 
known as long non-coding RNAs (lncRNAs)(5), which are defined as transcripts 
>200 nt in length (Figure 1A).  Over 14,000 have thus far been identified in 
humans(6), and they are currently sub-classified, based on their position relative to 
protein coding genes (Figure 1B), into antisense lncRNAs, pseudogene lncRNAs, 
enhancer RNAs, intronic lncRNAs and long intergenic ncRNA (lincRNA).  These 
multiple variants may in part explain the functional diversity that has thus far been 
assigned to lncRNAs(7), including inhibition of transcriptional machinery, functioning 
as miRNA sponges, affecting mRNA stability and epigenetic DNA modifications 
(Figure 2B, C, D).  Many of these functions have been attributed to the theory that 
lncRNAs form flexible scaffolds, which can bind proteins and RNAs.   
 
Importantly, increasing evidence suggests that lncRNAs are important regulators of 
pathological and physiological processes, and evidence is now emerging to suggest 
that lncRNAs are central regulators of the inflammatory response.  Therefore, in this 
review, we examine the evidence for the role of lncRNAs as regulators of 
inflammatory joint disease by highlighting studies which have reported differential 
expression of lncRNAs in diseased inflammatory joint tissue of patients with RA and 
OA, as well as studies which have implicated lncRNAs as regulators of known 
inflammatory pathways relevant to joint pathology. LncRNAs are poorly conserved 
across species, which has limited studies to determine their function. This poor 
conservation places great importance on the requirement to validate the function of 
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lncRNAs in disease-relevant human cells and tissue(8).  For this reason, this review 
will focus on lncRNA data generated from human tissue/cells.   
 
2.  LncRNAs regulate inflammatory pathways 
Inflammation is a central hallmark of RA joint disease, and evidence for inflammatory 
pathway dysregulation and cell dysfunction has been found in almost all innate and 
adaptive immune cells including. In addition, despite historically being seen as a 
“wear and tear” disease of the cartilage, there is now substantial evidence for 
inflammation also being a key contributor to OA joint pathology(9).  OA synovial 
inflammation (synovitis) has been shown histologically, as well as by ultrasound and 
MRI imaging(10, 11), and there is evidence for increased cellular infiltration of 
activated B cells and T lymphocytes, and elevated levels of pro-inflammatory 
cytokines in the synovial fluid(12).  Furthermore, ex-vivo stimulation of cartilage 
tissue with pro-inflammatory cytokines mimics several pathological features of the 
OA joint(13), and inhibitors of inflammatory pathways have modified OA disease in 
preclinical models(14). 
 
Below we examine the current evidence for the role of lncRNAs in regulating 
canonical inflammatory pathways that are relevant to inflammatory joint pathology. 
Of the major signaling pathways that are known to govern joint inflammation four 
pathways were currently highlighted as having lncRNAs associated with their 
regulation, namely NFκB signalling, p38 MAPK pathway, the arachidonic acid 
pathway and TLR signalling.  
 
2.1 NFκB Pathway 
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NFκB is considered a master regulator of inflammation, and its activity has been 
shown to regulate the production of several pro-inflammatory cytokines implicated in 
OA and RA joint pathology, including IL-1β, IL-6, IL-17 and TNF-α(12, 15). 
Therefore, inhibition of NFκB signalling has long been considered an attractive 
pathway to develop a therapeutic for chronic inflammatory disorders(15).  However, 
therapeutic targeting of NFκB presents a challenge since NFκB may also have an 
anti-inflammatory role and be important for the resolution of inflammation(16). 
Therefore, identifying new approaches to appropriately target the pro-inflammatory 
activity of NFkB within the joint(17), so that systemic effects are avoided and patients 
are not immunocompromised, is important. 
 
Thus far, several lncRNAs have been identified and implicated in targeting different 
components of the NFκB signalling pathway (Figure 3A). Of most immediate interest 
for inflammatory joint disease is lincRNA-p21, whose ability to inhibit NFκB signalling 
by sequestering RelA (the p65 subunit of NFκB) in T cells has been demonstrated 
following methotrexate treatment in RA patients. LincRNA-p21 expression was 
shown to be upregulated by methotrexate via a DNA-dependent protein kinase 
catalytic subunit (DNA PKcs)-dependent mechanism (18). 
 
Another lncRNA which has been implicated as regulating NFκB activity is the 
pseudogene Lethe, which has been shown to be expressed in fibroblasts.  
Functional studies have demonstrated that Lethe interacts with and blocks the DNA 
binding of RelA (p65).  It is believed that Lethe acts as part of a negative feedback 
loop which acts to regulate the inflammatory response, whereby following NFκB 
activation by pro-inflammatory cytokines, upregulation of Lethe inhibits NFκB 
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signalling. Of interest, the tissue expression of Lethe has been shown to be 
downregulated in aged mice (19). If the same is true in human ageing, the reduction 
in the expression of this potential brake on NFκB activity could be a contributing 
factor to age-associated inflammatory joint disorders such as RA and OA.  Finally, 
studies conducted in human inflammatory breast epithelial cells have shown that the 
lncRNA NKILA (NFκB-interacting lncRNA) binds to and blocks phosphorylation sites 
on IκB, thereby inhibiting IKK-induced IκB phosphorylation and NFκB activation (20). 
Thus far, there are no studies which have reported the functional role of lincRNA-
p21, Lethe or NKILA in RA or OA joint tissues or cells.   
 
2.2 Arachidonic Acid Pathway 
Arachidonic acid metabolites (prostaglandins and leukotrienes), are known 
mediators of the inflammatory response(21), and several have been found to be 
differentially expressed in the joints of patients with either OA or RA(22). Therefore, 
targeted inhibition of the arachidonic acid pathway has long been considered an 
important area of research for developing a therapeutic that combats joint 
inflammation and pain.  Indeed, inhibition of the prostaglandin synthase enzymes 
(COX enzymes) is the basis for the mode of action of non-steroidal anti-inflammatory 
drugs (NSAIDs) such as Ibuprofen(23) and selective PTGS2 (COX2) inhibitors such 
as Valdecoxib(24), which have shown efficacy in reducing joint inflammation in 
several clinical trials. 
 
Of importance therefore was the recent finding that the expression of PTGS2 
(COX2) was positively regulated by a p50-associated COX-2 extragenic lncRNA 
(Figure 3B), referred to as PACER (25). PACER was shown to bind to and remove 
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the repressive action of the p50 homodimer (of NFκB), at the COX2 promoter, 
leading to activation of COX-2 gene expression.  Furthermore, we recently found that 
the expression of PACER was associated with the IL-1β-mediated inflammatory 
response in primary human OA chondrocytes, and differentially expressed in human 
OA cartilage compared to non-OA cartilage (26).  
 
Unfortunately, long-term administration of non-selective NSAIDs are associated with 
gastrointestinal toxicity(27), whilst selective COX2 inhibitors increase the risk of 
cardiovascular adverse events(28), attributed to a resulting imbalance between 
Thromboxane and prostacyclin levels. Therefore, identifying new regulators of 
prostaglandin production, such as PACER, is important, since it may lead to new 
targeted approaches that are capable of selectively inhibiting the production of 
inflammation-associated arachidonic acid metabolites, without any resulting toxicity. 
 
2.3 p38 MAPK Signalling 
 Several studies have provided evidence that the p38 MAPK pathway is central to 
mediating both the production of pro-inflammatory cytokines and their signal 
transduction in the joint(13).  Furthermore p38 small molecule inhibitors have shown 
efficacy both in reducing cartilage degeneration in OA preclinical models(29, 30), 
and reducing inflammatory pain in RA models(14, 31), albeit clinical trials of p38 
inhibitors in patients with RA have thus far failed in the clinic. 
 
With regards to lncRNA regulation of the p38 pathway, recent studies suggest the 
involvement of the metastasis-associated lung adenocarcinoma transcript 1 
(MALAT1) (32) (Figure 3C). MALAT1 is one of the most abundantly expressed 
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lncRNAs, with high levels of conservation across multiple tissue types. It has 
previously been well characterised in cancer where it is a transcription regulator 
implicated in cell cycle control and metastasis. However, Liu and colleagues (2014) 
have now highlighted MALAT1 cross-talk with p38 MAPK as being pathogenic in 
diabetes mellitus. MALAT1 is believed to activate p38 MAPK, since siRNA mediated 
knockdown of MALAT1 reduced p38 phosphorylation (32).  Furthermore, MALAT1 
expression has been found to be implicated in inflammation, again in diabetes 
mellitus under hyperglycaemic conditions, where it was shown to contribute to 
increased IL-6 expression and reactive oxygen species (ROS) generation(33). 
 
2.4 TLR Signalling 
Innate immune cells such as macrophages and neutrophils are present in the 
inflamed joints of RA and OA patients, and it is known that Toll-like receptor (TLR) 
signalling plays a key role in the recruitment and activation of these cells. Therefore, 
understanding the regulation of cytokine and chemokine signalling by these cells will 
provide greater clues as to the onset and maintenance of chronic inflammation within 
the joint. 
 
TNFα and hnRNPL related immunoregulatory LincRNA (THRIL) was recently 
identified in macrophages as a lncRNA which could form a complex with 
heterogeneous ribonucleoprotein L (hnRNPL) within the nucleoplasm (Figure 3D).  
hnRNPs are known to be important for the processing, function and stabilisation of 
mRNAs. Critically, it was demonstrated that the THRIL/hnRNPL complex binds to the 
promotor of TNFα and induces its expression following TLR2 activation(34). 
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Carpenter and colleagues(35) identified a lncRNA (lincRNA-COX2) that sits in close 
proximity to the PTGS2 gene but, unlike the aforementioned PACER, this lncRNA 
had no functional interaction with PTGS2.  Instead, lncRNA-COX2 was shown to be 
upregulated following activation of the TLR2 pathway (Figure 3D). Furthermore, 
following knockdown of lincRNA-COX2 and under the challenge of a synthetic TLR2 
antagonist, expression of IL-6 became undetectable, while CCL5 expression 
increased. Similarly to THRIL, lincRNA-COX2 forms complexes with hnRNPs, 
specifically hnRNP-A/B and hnRNP-A2/B1, and the formation of such complexes has 
been shown to modulate target gene expression. 
 
Activation of TLR3 has been shown to induce a lncRNA referred to as NEAT1 
(nuclear enriched abundant transcript 1).  NEAT1 was found to bind to a repressor of 
IL-8 transcription known as SFPQ (splicing factor proline/glutamine-rich) and 
relocate it to paraspeckle bodies (Figure 3D), resulting in IL-8 transcriptional 
activation(36). Ilott and colleagues(37) demonstrated that TLR4 activation in 
monocytes up-regulated expression of a lncRNA known as IL1β-RBT46. IL1β-
RBT46 shares a promotor with the IL-1β coding gene and following pathway 
activation, both expression of the lincRNA and the IL-1β gene are induced (Figure 
3D).  LNA-mediated knockdown of IL1β-RBT46 led to a decrease in IL-1β mRNA 
expression, suggesting that the lincRNA promotes expression of the gene. A further 
consequence of IL1β-RBT46 knockdown was a reduction in expression of IL-8, a 
well-defined neutrophil chemoattractant. 
 
Taken together, the lncRNAs described above represent a pool of lncRNAs, which 
have not as yet been associated with inflammatory joint disease. However, given 
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their prevalence in the regulation of central pathways of inflammation, determining 
their expression in joint tissues, and the relationship to OA and/or RA joint pathology 
would appear to be important studies.   
 
The significance of genetic variations in the sequences of lncRNAs is currently not 
well understood and has been little studied to date.  There is evidence that large 
alterations such as chromosomal rearrangements can affect lncRNA expression(38).  
However, as illustrated by the functional studies highlighted in this review, lncRNA 
function may largely be determined by its secondary structure, through binding to 
proteins and RNA.  Therefore, smaller mutations and genetic variations such as 
SNPs may have little effect on lncRNA function.  It is conceivable that SNPs could 
alter lncRNA function by altering lncRNA secondary structure, or causing alternative 
splicing of the lncRNA.  Indeed, there is evidence of SNPs in the chromosomal 
region that harbour the lncRNA ANRIL being associated with a susceptibility to 
cardiovascular disorders(39).  However, it is not currently known whether these 
SNPs impact on the functional role of ANRIL lncRNA, or simply affect its expression.   
Predominantly therefore, studies have thus far linked lncRNA to disease by 
expression analysis. 
 
3.  LncRNA expression in inflammatory OA and RA joint tissues 
Transcriptional analyses by both NGS and microarray have identified several 
lncRNAs that are differentially expressed in inflammatory diseased joint tissue.  Thus 
far, studies on OA patient samples have focussed on the cartilage tissue, whilst in 
RA disease other peri-joint tissues such as synovium and sub-chondral bone have 
been interrogated.   
Page 35 of 51
John Wiley & Sons
Arthritis & Rheumatology
For Peer Review
12 
 
 
One lncRNA that has been found to be differentially expressed in both OA and RA 
joint tissue is HOTAIR.  Located on chromosome 12, HOTAIR was the first lncRNA 
to be characterised, and has been shown to interact with polycomb repressive 
complex 2 (PRC2) which regulates the chromatin state, and the histone 
demethylase, LSD1. As such, it regulates epigenetic changes within its target 
transcripts(40).  
 
In OA cartilage, HOTAIR was found to be upregulated compared to non-OA cartilage 
(41), although as yet its function in cartilage tissue or in isolated chondrocyte cells 
has yet to be reported.  Song et al (42) have also identified differential expression of 
HOTAIR in RA peri-joint tissues, namely synovial fibroblasts, osteoclasts and bone 
mononuclear cells. Of note, Song et al (42) found that the function of HOTAIR 
differed depending on the RA cell studied. For example, in RA synovial fibroblasts 
and osteoclasts, HOTAIR expression was lower than in controls and its over-
expression decreased the expression of MMP2 and MMP13.  In contrast, HOTAIR 
was upregulated in RA bone mononuclear cells where it functioned to facilitate 
macrophage activation and migration towards the joint. 
 
Another lncRNA for which differential expression has been reported in inflamed joint 
tissue is H19.  H19 lncRNA has been found to be highly expressed in RA synovial 
tissues RA(43) and in OA cartilage(44).  Previous studies have demonstrated that 
H19 is a developmental reservoir of the two miR-675 family members – miR-675-p3 
and miR-675-p5, which have been shown to regulate Type II Collagen expression 
and mediate cellular development in multiple tissues (45-47).  Of interest, numerous 
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studies have demonstrated that H19 controls the expression of several genes which 
are part of the Imprinted Gene Network (IGN) – a series of parentally inherited genes 
whose expression is epigenetically determined within the sperm or oocyte. Such 
“imprinting disorders” have been linked to a number of human pathologies. Currently, 
inflammatory disease isn’t known to be affected by imprinting disorders, but given 
the inheritability of RA and other inflammatory diseases, studies which investigate 
the role of H19 in determining epigenetic susceptibility to disease could be of 
interest. 
  
As previously mentioned, lncRNA analysis in OA has primarily focused on the 
cartilage tissue, and the lncRNAs GAS5(48) and MEG3(49) have been reported to 
be downregulated in OA diseased cartilage. Fu and colleagues(50) performed 
microarray analysis  and identified 4714 lncRNAs which were differentially expressed 
in OA cartilage compared to non-OA cartilage.  Although this study did not perform 
any modulation of lncRNA expression to determine lncRNA function, expression 
correlation patterns were utilised to predict candidate lncRNA regulated genes.   This 
analyses highlighted lncRNAuc.343, which was upregulated in OA cartilage, as 
regulating in cis the expression of HOXC8(50), and that many of the differentially 
expressed lncRNAs worked in concert with the transcription factor, SP1, to modulate 
expression of trans target genes. 
 
In a separate study, microarray analysis was used to identify a lncRNA with a 
specific role in the degradation of the cartilage matrix, named lncRNA-CIR.  
LncRNA-CIR was found to be upregulated in OA cartilage, compared to non-OA 
cartilage, and siRNA-mediated knockdown of its expression resulted in the increased 
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expression of collagen and aggrecan accompanied by reduced expression of 
MMP13 and ADAMTS5 (51). 
  
Furthermore, we recently identified lncRNAs associated with the IL-1β-mediated 
inflammatory response in primary human OA chondrocytes, which were also 
differentially expressed in OA diseased cartilage.  Of particularly note were 
HIVEP2AS and IL-7AS, two intergenic lncRNAs proximal to the Hivep2 and IL-7 
protein coding genes respectively(26).  Both HIVEP2AS and IL-7AS were found to 
be upregulated in both Knee OA and hip OA cartilage compared to non-OA control 
cartilage(26).  Furthermore, LNA-mediated knockdown of HIVEP2AS and IL-7AS 
expression in human chondrocytes resulted in an increase in the production of pro-
inflammatory cytokines, including IL-6(26), suggesting that these lncRNAs may 
function to control aberrant joint inflammation.   
 
4.  Perspectives 
LncRNA research in inflammatory joint disease is very much a nascent field.  
However, several lncRNAs have now been identified as being either differentially 
expressed in diseased joint tissue, or as candidate central regulators of inflammatory 
pathways relevant to joint pathology.  Therefore, future studies to determine the 
functional role and mode of action of these disease-associated lncRNAs will be 
insightful, as will joint tissue expression profiling of lncRNAs for which functional 
roles within key inflammatory pathways have been determined.  To this end, it will be 
important to conduct further transcriptomic analysis of joint tissues (including 
subchondral bone, cartilage, and synovium), where diseased joint tissues are 
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compared with age-matched non-inflammatory control joint tissue, and to conduct 
functional mode-of-action studies in disease relevant cells.   
 
It should be noted that currently the expression analysis of lncRNAs in the joint 
tissues from patients with other inflammatory joint diseases including gout, psoriatic 
arthritis and juvenile idiopathic arthritis has not yet been reported. Clearly, such 
studies could also prove to be informative in building a broader pool of inflammatory 
joint disease-associated lncRNAs.  Indeed, since inflammatory joint diseases share 
several common pathways, such studies are likely to identify lncRNAs that are 
dysregulated across multiple inflammatory joint disorders.  Such findings will add to 
the recent paradigm shift in our understanding of the dysregulation of chronic 
disease, whereby the disease is no longer classified solely by its gross pathology but 
by the involvement of a particular dysregulated pathway.    
 
It is currently too early to determine whether disease modifying therapeutics could be 
developed that are designed to directly target and modulate lncRNA function.  
Recent progress has been achieved using siRNA RNAi-based therapeutics, whereby 
targeted knockdown of TNF-α (52) or NFĸB (53) has modified disease progression in 
animal models of RA and OA.  Therefore, it is conceivable that lncRNAs could 
provide a new class of targets for RNAi based therapeutics.  Regardless, ultimately 
determining the mode of action of lncRNAs that regulate inflammatory pathways,  
and determining their relationship to joint pathology will provide a better 
understanding of how inflammation is epigenetically regulated within the joint.  This 
improved understanding will likely be important in aiding the identification of new 
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targets for therapeutic intervention, as well as in identifying at risk patient 
populations.    
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Table 1: LncRNA involvement in inflammatory pathways 
Pathway LncRNA Tissue/Cell Chromosome 
Locus 
Function Reference 
NFκB Signalling LincRNA-
p21 
T cells 6p21.2 Inhibition of NFκB following methotrexate treatment Spurlock et al 
2014(18) 
 NKILA Epithelial cells 20q13.31 Inhibition of IκB phosphorylation Liu et al 
2015(20) 
 Lethe Fibroblasts Not reported Inhibition of RelA DNA binding Rapicavoli et al 
2013(19) 
p38 MALAT1 Endothelial 
cells 
11q13.1 Reduced p38 phosphorylation and inaction of p38 MAPK signalling Liu et al 
2014(32) 
Puthanveetil et al 
2015(33) 
Arachidonic Acid  PACER Epithelial cells 1q31.1 Inhibition of COX-2 Krawczyk et al 
2014(25) 
TLR THRIL Macrophages 12q24.31 Complex formation with hnRNPL to induce TNFα expression Li et al 2014(34) 
 IL1β-RBT46 Monocytes 2q14 Inhibition of IL-1β and IL-8 secretion Ilott  et al  
2014(37) 
 LincRNA-
COX2 
Bone marrow 
dendritic cells 
1q31.1 Up-regulation of IL-6 and down-regulation of CCL5 Carpenter et al 
2013(35) 
 NEAT1 HeLa 11q13.1 Activated by p38 leading to expression of IL-8 Imamura et al 
2014(36) 
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Table 2: Evidence for the differential expression of lncRNAs in OA and RA joint tissues 
Disease LncRNA Tissue/Cell Chromosome 
Locus 
Disease Expression Function Reference 
OA Hivep2-AS (CILinc01) Chondrocytes 6q23-q24 Upregulated Suppresses IL-6, IL-8, TNFα, G-CSF, 
MIP-1β 
Pearson  et al 2016(26) 
 IL-7AS (CILinc02) Chondrocytes 8q12-q13 Upregulated Suppresses IL-6 Pearson et al 2016(26) 
 H19 Chondrocytes 11p15.5 Upregulated Anabolic functions Steck et al 2012(44) 
 LncRNA-CIR Chondrocytes 6q22.32 Upregulated Promotes expression of MMP-13 
and ADAMTS5 while inhibiting 
collagen and aggrecan production 
Liu et al 2014(51) 
 MEG3 Cartilage 14q32.2 Downregulated Inversely correlated with VEGF Su et al 2015(49) 
 HOTAIR Cartilage 12q13.13 Downregulated Unknown Xing et al 2014(41) 
 GAS5 Cartilage 1q25.1 Downregulated Increase expression of MMPs and 
ADAMTS4. Induced apoptosis 
Song et al 2014(48); 
Xing et al 2014(41) 
 lncRNAuc.343 Cartilage Not reported Upregulated Regulation of HOXC8 Fu et al 2015(50) 
RA H19 Synovium 11p15.5 Upregulated Increases expression of NFκB, IL-6, 
TNFα 
Stuhlmüller et al 
2003(43) 
 HOTAIR Synovial fibroblasts, 
osteoclasts 
12q13.13 Downregulated Increased MMP2 and MMP13 
expression 
Song et al 2015(42) 
 HOTAIR Bone mononuclear 
cells 
12q13.13 Upregulated Migration and activation of 
macrophages 
Song et al 2015(42) 
 LincRNA-p21 T cells 6p21.2 Downregulated 
(Upregulated following 
methotrexate treatment) 
Inhibition of NFκB following 
methotrexate treatment  
Spurlock et al 
2014(18) 
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Figure Legends 
 
Figure 1.  Classification of non-coding RNAs and lncRNA sub-types 
(A)  LncRNAs are classified as being >200 nt in length, in contrast to miRNAs which 
are <200 nt long.  (B)  LncRNAs are further classified by their position relative to 
protein-coding genes.  Intronic lncRNAs are transcribed from intronic transcription 
start sites (TSS) and can be in either sense of antisense orientation.  They do not 
intersect any exons.  In contrast, Antisense lncRNAs are transcribed across protein-
coding exons on the opposite strand.  Intergenic lncRNAs (lincRNAs) are transcribed 
from TSS between protein-coding genes.  Pseudogenes can be classified as a type 
of lincRNA and originate when a gene loses its coding ability, for example through a 
mutation.  Enhancer RNAs (eRNAs) can also be considered a type of lincRNA, but 
are transcribed from enhancer regions (identified by the presence of high H3K4me1 
histone marks).  In contrast, other lncRNAs are transcribed from regions associated 
with the presence of high H3K4me3 histone marks, similar to protein-coding genes. 
   
Figure 2.  Functional diversity attributed to lncRNAs. 
(A) Post-transcriptional regulation of gene expression by non-coding miRNAs.  
miRNAs bind to the 3’UTR of target mRNAs in the cytoplasm.  Assembly of a RNA 
induced silencing complex (RISC), composed of Ago2, Dicer and R2D2, leads to 
mRNA degradation.  Conversely, lncRNAs can modulate gene expression through 
both pre- and post-transcriptional regulation mechanisms.  (B) LncRNAs can act as 
scaffolds for the assembly of complexes that epigenetically modify the DNA (e.g  
histone acetylation and methylation), leading to modulation of transcription.  (C) 
LncRNAs can bind to transcription factors and mediate assemble of transcription 
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initiation complexes, leading to modulation of transcription.  (D) LncRNAs can bind to 
miRNAs, acting as either sponges to block their activity, or affect miRNA stability. 
 
Figure 3.  Functional lncRNAs in inflammatory pathways.  (A)  Canonical NFĸB 
signalling.  The lncRNA NKILA blocks the Iĸβα phosphorylation site preventing its 
activation.  The lncRNAs Lethe and LincRNA-p21 both bind to RelA and prevent 
NFĸB binding to NFĸB response elements.  (B)  Arachidonic acid pathway.  The 
lncRNA PACER binds to and removes the repressive action of the p50 homodimer at 
the COX2 promoter, leading to activation of COX-2 gene expression.  (C)  p38 
MAPK signalling.  The lncRNA MALAT1 activates p38 phosphorylation.  ARE 
represents Adenine Rich Elements in mRNA transcripts, which are stabilised via 
downstream MK2 activation.  (D)  TLR signalling.  The lncRNAs THRIL and 
LincRNA-COX2 form complexes with hnRNPLs, which then bind to and activate the 
promoters of pro-inflammatory cytokines TNF-α and CCL5 respectively.  The lncRNA 
NEAT1 binds to SFPQ and relocates it to paraspeckle bodies, relieving its repression 
of the IL-8 promoter.  The IL1β-RBT46 is induced by TLR4 signalling and promotes 
induction of IL-8 and IL-1β via an as yet unknown mechanism. 
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Figure 2.  Functional diversity attributed to lncRNAs.  
(A) Post-transcriptional regulation of gene expression by non-coding miRNAs.  miRNAs bind to the 3’UTR of 
target mRNAs in the cytoplasm.  Assembly of a RNA induced silencing complex (RISC), composed of Ago2, 
Dicer and R2D2, leads to mRNA degradation.  Conversely, lncRNAs can modulate gene expression through 
both pre- and post-transcriptional regulation mechanisms.  (B) LncRNAs can act as scaffolds for the 
assembly of complexes that epigenetically modify the DNA (e.g  histone acetylation and methylation), 
leading to modulation of transcription.  (C) LncRNAs can bind to transcription factors and mediate assemble 
of transcription initiation complexes, leading to modulation of transcription.  (D) LncRNAs can bind to 
miRNAs, acting as either sponges to block their activity, or affect miRNA stability.  
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Figure 3. Functional lncRNAs in inflammatory pathways. (A) Canonical NFĸB signalling. The lncRNA NKILA 
blocks the Iĸβα phosphorylation site preventing its activation. The lncRNAs Lethe and LincRNA-p21 both bind 
to RelA and prevent NFĸB binding to NFĸB response elements. (B) Arachidonic acid pathway. The lncRNA 
PACER binds to and removes the repressive action of the p50 homodimer at the COX2 promoter, leading to 
activation of COX-2 gene expression. (C) p38 MAPK signalling. The lncRNA MALAT1 activates p38 
phosphorylation. ARE represents Adenine Rich Elements in mRNA transcripts, which are stabilised via 
downstream MK2 activation. (D) TLR signalling. The lncRNAs THRIL and LincRNA-COX2 form complexes with 
hnRNPLs, which then bind to and activate the promoters of pro-inflammatory cytokines TNF-α and CCL5 
respectively. The lncRNA NEAT1 binds to SFPQ and relocates it to paraspeckle bodies, relieving its repression 
of the IL-8 promoter. The IL1β-RBT46 is induced by TLR4 signalling and promotes induction of IL-8 and IL-
1β via an as yet unknown mechanism.  
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